炎症性肠病与非酒精性脂肪性肝病的关系(2)
參考文献
[1]Bringiotti R， Ierardi E， Lovero R， Losurdo G， Di Leo A， Principi M. Intestinal microbiota： The explosive mixture at the origin of inflammatory bowel disease？ World J Gastrointest Pathophysiol 2014; 5： 550-559.
[2]Gisbert JP， Luna M， González-Lama Y， Pousa ID， Velasco M， Moreno-Otero R， Maté J. Liver injury in inflammatory bowel disease： long-term follow-up study of 786 patients. Inflamm Bowel Dis 2007; 13： 1106-1114.
[3]Sourianarayanane A， Garg G， Smith TH， Butt MI， McCullough AJ， Shen B. Risk factors of non-alcoholic fatty liver disease in patients with inflammatory bowel disease. J Crohns Colitis 2013; 7： e279-e285.
[4]Liu TC， Stappenbeck TS. Genetics and Pathogenesis of Inflammatory Bowel Disease. Annu Rev Pathol 2016; 11： 127-148.
[5]Nagahori M， Hyun SB， Totsuka T， Okamoto R， Kuwahara E， Takebayashi T， Naganuma M， Watanabe M. Prevalence of metabolic syndrome is comparable between inflammatory bowel disease patients and the general population. J Gastroenterol 2010; 45： 1008-1013.
[6]Bessissow T， Le NH， Rollet K， Afif W， Bitton A， Sebastiani G. Incidence and Predictors of Nonalcoholic Fatty Liver Disease by Serum Biomarkers in Patients with Inflammatory Bowel Disease. Inflamm Bowel Dis 2016; 22： 1937-1944.
[7]Bath RK， Brar NK， Forouhar FA， Wu GY. A review of metho- trexate-associated hepatotoxicity. J Dig Dis 2014; 15： 517-524., 百拇医药(白旻昱 陈绪丰 殷雯雯)
[1]Bringiotti R， Ierardi E， Lovero R， Losurdo G， Di Leo A， Principi M. Intestinal microbiota： The explosive mixture at the origin of inflammatory bowel disease？ World J Gastrointest Pathophysiol 2014; 5： 550-559.
[2]Gisbert JP， Luna M， González-Lama Y， Pousa ID， Velasco M， Moreno-Otero R， Maté J. Liver injury in inflammatory bowel disease： long-term follow-up study of 786 patients. Inflamm Bowel Dis 2007; 13： 1106-1114.
[3]Sourianarayanane A， Garg G， Smith TH， Butt MI， McCullough AJ， Shen B. Risk factors of non-alcoholic fatty liver disease in patients with inflammatory bowel disease. J Crohns Colitis 2013; 7： e279-e285.
[4]Liu TC， Stappenbeck TS. Genetics and Pathogenesis of Inflammatory Bowel Disease. Annu Rev Pathol 2016; 11： 127-148.
[5]Nagahori M， Hyun SB， Totsuka T， Okamoto R， Kuwahara E， Takebayashi T， Naganuma M， Watanabe M. Prevalence of metabolic syndrome is comparable between inflammatory bowel disease patients and the general population. J Gastroenterol 2010; 45： 1008-1013.
[6]Bessissow T， Le NH， Rollet K， Afif W， Bitton A， Sebastiani G. Incidence and Predictors of Nonalcoholic Fatty Liver Disease by Serum Biomarkers in Patients with Inflammatory Bowel Disease. Inflamm Bowel Dis 2016; 22： 1937-1944.
[7]Bath RK， Brar NK， Forouhar FA， Wu GY. A review of metho- trexate-associated hepatotoxicity. J Dig Dis 2014; 15： 517-524., 百拇医药(白旻昱 陈绪丰 殷雯雯)